Nouri Neamati, PhD

Nouri Neamati is the John G. Searle Professor of Medicinal Chemistry at the University of Michigan College of Pharmacy. He obtained a Ph.D. in biomedical sciences from the University of Texas Graduate School of Biomedical Sciences and M.D. Anderson Cancer Center, Houston, Texas in 1995. From 1995 to 2000 he was a postdoctoral fellow and a research fellow at the National Institutes of Health. In September 2000, he joined the University of Southern California School of Pharmacy with a joint appointment at the Norris Comprehensive Cancer Center, rising to the rank of professor in 2011. 


Scott Tomlins, MD, PhD

Scott A. Tomlins, M.D., Ph.D., obtained his M.D. and Ph.D. at the University of Michigan Medical School (UMMS). His thesis, completed under the mentorship of Arul Chinnaiyan, M.D., Ph.D., described the identification and characterization of recurrent ETS gene fusions in prostate cancer. He completed residency in Anatomic Pathology at the University of Michigan Health System in June 2012 and is an Assistant Professor of Pathology and Urology, and a member of the Michigan Center for Translational Pathology (MCTP) at UMMS. Dr.

David Lombard, M.D., Ph.D.

Dr. Lombard received a Ph.D. in Biology from Massachusetts Institute of Technology (2000) and an M.D. from Harvard Medical School (2001). He completed residency training in Anatomic Pathology (2001-2003) at Brigham and Women's Hospital in Boston. Following residency training Dr. Lombard joined the laboratory of Professor Frederick Alt at Children's Hospital as a Posdoctoral Fellow. He continued in this role until joining the faculty of the Department of Pathology in September 2008.

Thomas Wilson, M.D., Ph.D.

Dr. Wilson received his MD PhD from Washington University in St. Louis in 1994, where he studied mechanisms of DNA binding by transcription factors with Dr. Jeffrey Milbrandt. He continued at Washington University to complete residency training in Clinical Pathology, as well as a postdoctoral fellowship in DNA repair with Dr. Michael Lieber. Dr. Wilson joined the faculty at the University of Michigan in 1999 and now holds the rank of Professor. Dr. Wilson pursues basic research into molecular mechanisms of DNA repair and associated mutagenesis in the germline and cancer genomes.

Max Wicha, M.D.

As founding director of the UM Comprehensive Cancer Center, Dr. Wicha is responsible for coordinating all cancer activities related to research and patient care.  Dr. Wicha is nationally known for his research in the field of breast oncology. His lab was part of the team that first discovered stem cells in breast cancer, the first described in any human solid tumor.  Since then, Dr. Wicha has become one of the leading experts on cancer stem cells. Dr. Wicha is also active as a clinician, specializing in the treatment of breast cancer patients.